Fate Therapeutics (FATE)

P/S ratio as of November 2026 (TTM): 37.6

According to Fate Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.59. At the end of 2026 the company had a P/S ratio of 37.7.

P/S ratio history for Fate Therapeutics from 2013 to 2026

PS ratio at the end of each year

Year	P/S ratio	Change
2026	37.7	120.26%
2025	17.1	27.27%
2024	13.5	131.76%
2023	5.80	-42.99%
2022	10.2	-89.82%
2021	100	-60.36%
2020	252	81.87%
2019	139	-20.75%
2018	175	123.55%
2017	78.3	231.94%
2016	23.6	-40.72%
2015	39.8
2014	N/A	-100%
2013	132

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Becton Dickinson BDX	2.58	-93.13%	🇺🇸 USA
Sarepta Therapeutics SRPT	0.9873	-97.37%	🇺🇸 USA
PTC Therapeutics PTCT	5.05	-86.55%	🇺🇸 USA
Neurocrine Biosciences NBIX	4.42	-88.24%	🇺🇸 USA
Avidity Biosciences RNAM	600	1,496.68%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Fate Therapeutics (FATE)

P/S ratio as of November 2026 (TTM): 37.6